In the COVID-19 era, expert opinion on the treatment of patients with psoriasis and heart failure with MTX, retinoids, and ustekinumab, IL-17, and IL-23 inhibitors is neutral, depending on the underlying cause of heart failure. Here, IL17A is linked to psoriasis.